黑色素瘤
GNAQ公司
医学
临床研究阶段
临床终点
癌症研究
不利影响
癌症
药代动力学
内科学
毒性
药品
药理学
临床试验
肿瘤科
化疗
转移性黑色素瘤
黑素细胞
皮肤病科
作者
Matteo Salvatore Carlino,Ellen Kapiteijn,Sophie Piperno-Neumann,Ryan Joseph Sullivan,Richard D. Carvajal,Reinhard Dummer,Tanja Gromke,Jessica C. Hassel,Damien Kee,Egle Ramelyte,Alexander Noor Shoushtari,Alexander Z. Wei,Alexander Enk,Eleanor E. Handel,Kamaneh Montazeri,Jorge Ramon-Patino,Heike Richly,Manuel Jorge Rodrigues,Shahneen Kaur Sandhu,James William Smithy
出处
期刊:Nature Medicine
[Nature Portfolio]
日期:2026-07-13
卷期号:32 (9): 3248-3258
被引量:2
标识
DOI:10.1038/s41591-026-04518-z
摘要
Abstract Metastatic uveal melanoma (mUM) is an aggressive cancer with limited treatment options; 85−90% of tumors harbor activating GNAQ and GNA11 mutations. Uveal melanoma cells also express PMEL (also known as PMEL17 or gp100), a melanocyte lineage antigen. DYP688, a novel biology-matched antibody−drug conjugate, binds surface PMEL and delivers the potent Gα q /Gα 11 (G q/11 ) inhibitor SDZ475 as payload by internalization. This dose-escalating first-in-human phase 1 study of DYP688 in patients with metastatic uveal melanoma and other GNAQ / GNA 11 -mutant melanomas assessed safety as the primary endpoint and pharmacokinetics and preliminary antitumor activity as secondary endpoints. Sixty-six patients received varying DYP688 doses and schedules. Grade 3 treatment-related adverse events occurred in five patients (7.6%), including one dose-limiting toxicity of grade 3 hypotension. Objective responses were seen in 13 out of 66 patients (19.7%) and tumor reduction in 47 out of 66 patients (71.2%). Median progression-free survival was 7.2 (95% CI: 5.3–7.8) months. In summary, DYP688 was well tolerated and showed preliminary efficacy, supporting this novel therapeutic approach. ClinicalTrials.gov identifier: NCT05415072 .
科研通智能强力驱动
Strongly Powered by AbleSci AI